Report by Simon Collins, HIV i-Base
On 31 May 2026, UKHSA published new guidance on the continued use of the 4CMenB vaccine in a sexual health programme aimed to reduce the incidence of gonorrhoea in gay and bisexual men.
The guidance is needed because two months ago results from the large Australian GoGoVax trial, presented at CROI 2026, failed to show any protection in almost 600 gay and bisexual men randomised to either vaccine or placebo.
The lively Q&A debate after the presentation divided opinion. Many scientists thought that this data – the third randomized controlled trial to not show a benefit – provided conclusive evidence on the lack of effect. Others, including the study presenter, cautiously want to wait for results from other ongoing studies in the hope they might support observational studies that have shown small but significant benefits.
Read the full report here.
Source : HIV i-Base
Related HIV and Co-Infections News
-
ECDC: Clusters of dermatophilosis in five EU/EEA countries in 2025–2026
-
[Press release] FDA accepts Gilead’s application for investigational once-weekly oral Yeztugo, potentially the first long-acting pill for HIV prevention
-
WHO launches first global database on the prevalence of sexually transmitted infections
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.